DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio Now
by Zacks Equity Research
ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.
Here's Why DaVita HealthCare (DVA) Fell More Than Broader Market
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $163.16, moving -0.65% from the previous trading session.
MASI Stock Gains as US Court Raises Concern About Politan's Ethics
by Zacks Equity Research
Shares of Masimo have risen since the news of a court ruling against Politan. The ruling is likely to favor MASI's founder in the upcoming vote for new board members on Sept. 19.
Stryker Stock Declines Despite Completion of care.ai Acquisition
by Zacks Equity Research
SYK completes the acquisition of care.ai, adding AI-based workflows and smart room technology to its portfolio to overcome nursing shortages, and improve staff retention and workplace safety.
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, DaVita HealthCare (DVA) closed at $164.22, indicating a -0.59% shift from the previous trading day.
Masimo's Stock Up Following the New Tie-Up With Google to Boost Wear OS
by Zacks Equity Research
MASI's latest partnership is likely to develop a new reference platform that brings high-performing Wear OS smartwatches to market.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan
by Zacks Equity Research
The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience.
Zacks Investment Ideas feature highlights: Intuitive Surgical, SharkNinja and DaVita
by Zacks Equity Research
Intuitive Surgical, SharkNinja and DaVita have been highlighted in this Investment Ideas article.
5 Stocks to Benefit From Relative Price Strength Trends
by Nilanjan Choudhury
LMB, UI, RCL, DVA and BOOT are five stocks with explosive relative price strength.
3 Red Hot Stocks Flashing Buy Signals: DVA, ISRG, SN
by Derek Lewis
Stocks making new highs tend to make even higher highs, particularly when positive earnings estimate revisions hit the tape. And that's precisely what these three companies have seen.
DaVita Inc. (DVA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
by Zacks Equity Research
NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
SYK Stocks Gains Following Expansion of Foot & Ankle Portfolio
by Zacks Equity Research
Stryker unveils two new products, enhancing precision and outcomes in foot and ankle surgeries.
Factors Driving Veeva Stock More Than 20% in Three Months
by Zacks Equity Research
Robust quarterly results on the back of new partnerships and rising subscription revenues are driving VEEV's shares.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DaVita HealthCare (DVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $153.99, denoting a +0.29% change from the preceding trading day.
Are Investors Undervaluing DaVita (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Adagene (ADAG) This Year?
by Zacks Equity Research
Here is how Adagene Inc. Sponsored ADR (ADAG) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Glaukos Stocks Rides on Strong Product Demand Amid Competition
by Zacks Equity Research
GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
MASI Stock Down Despite New SafetyNet Deal for Neonatal Care
by Zacks Equity Research
The latest adoption of Masimo's SafetyNet is likely to improve the care provided to premature newborns and facilitate their early discharge from the hospital.
DaVita HealthCare (DVA) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why You Should Retain PDCO Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies on the back of its broad product line.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
by Zacks Equity Research
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
VEEV Stock Up Following the Release of New Features of Veeva Site Connect
by Zacks Equity Research
Veeva Systems' Site Connect is likely to aid the sponsors in reducing trial time and expense.